Abdul Qadir Memon A, Shamim A, Mirza S, Osama M, Naeem Muhammad I, R Wei C. Mavacamten: A Review of a Novel Therapeutic Approach for Hypertrophic Cardiomyopathy.
Cardiovasc Hematol Agents Med Chem 2024:CHAMC-EPUB-139602. [PMID:
38584533 DOI:
10.2174/0118715257283752240325082733]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2023] [Revised: 03/02/2024] [Accepted: 03/08/2024] [Indexed: 04/09/2024]
Abstract
Hypertrophic Cardiomyopathy (HCM) is a heart disease that can cause left ventricular hypertrophy, arrhythmias, heart failure, and sudden cardiac death. Currently, pharmacological treatment is limited and ineffective. Mavacamten (CamzyosTM) is a cardiac myosin inhibitor developed as a therapeutic option to reduce myocardial contractility and restoration of myocardial function. The Food and Drug Administration (FDA) approved the use of Mavacamten in 2022 for HCM symptoms. Clinical studies have proven that Mavacamten can reduce Left Ventricular Outflow Tract (LVOT) involvement, cardiac hypercontraction, and hypertrophy. This review provides an overview of HCM, its pathophysiology, current treatments, synthesis of Mavacamten, and the clinical trials of Mavacamten.
Collapse